Skip to main content
Clinical Trials/NCT01452841
NCT01452841CompletedNot Applicable

Efficiency of Daily Grapefruit Exposure in Reducing Body Weight and Inflammatory Markers

University of Arizona2 sites in 1 country85 target enrollmentStarted: August 2009Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
85
Locations
2
Primary Endpoint
Weight reduction

Study Overview

Brief Summary

Folklore has suggested that consuming grapefruit may promote weight control. Sparse data exist to support this hypothesis, though there is some evidence of health promotional effects regarding blood pressure and lipid profiles. The aims of this randomized controlled trial are to determine the role of grapefruit in:

  1. Reducing weight
  2. Reducing blood pressure
  3. Reducing inflammation
  4. Improving the lipid profile.

The investigators hypothesize that six weeks of daily consumption of grapefruit will reduce weight, blood pressure, and inflammation while improving the lipid profile in overweight, healthy adults.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Adults, men and premenopausal women
  • BMI: 25-45 kg/m2
  • Willing to maintain current exercise regimen (not to exceed 10 hours/week)
  • Willing to follow a diet low in bioactive rich fruits and vegetables and with no citrus

Exclusion Criteria

  • History of chronic disease
  • Metabolic disease
  • Inflammatory disease
  • High cholesterol (>225 mg/dL)
  • Taking medications metabolized by the Cytochrome P450 3A enzyme
  • History of alcohol or drug abuse

Outcomes

Primary Outcomes

Weight reduction

Time Frame: 6 weeks

Participants consumed 1/2 grapefruit before each meal (1.5 grapefruit per day) for six weeks. Weight was measured before and after grapefruit consumption to assess weight change. Weight change was considered statistically significant at p\<0.05.

Secondary Outcomes

  • Reductions in markers of chronic inflammation(6 weeks)
  • Blood pressure reduction(6 weeks)
  • Lipid Profile Improvements(6 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials